Prediction of potentially lethal forms of prostate cancer

An international, multi-institutional group of researchers appears to have been able to validate a new way to predict risk for aggressive forms of localized prostate cancer that have a high probability for progression to metastatic disease and prostate cancer-specific mortality. … READ MORE …

Prostate cancer and its management: where we are at now

A relatively long article in the June 21 issue of US News & World Report discusses a series of topical issues related to the diagnosis and management of prostate cancer, including: … READ MORE …

What is “Prostac” and where can you get it?

Someone asked the sitemaster yesterday about a new test for risk of prostate cancer called Prostac® and where he could access this. … READ MORE …

Are genomic tests for prognostic risk at diagnosis really helpful (yet)?

One of the critical and unanswered questions about the value of genomic/genetic testing in relation to the diagnosis and prognosis of prostate cancer is, “What are the currently available tests actually telling us compared to the clinical data?” … READ MORE …

Medicare to cover genetic/genomic testing in advanced cancers

In an important decision announced late on Friday last week, the Centers for Medicare & Medicaid Services (CMS) announced that it had agreed to cover costs associated with genetic/genomic testing for Medicare patients with many advanced forms of cancer. … READ MORE …

Genomic testing and management of low-/intermediate-risk prostate cancer

A new paper has provided us with data on the ability of genomic testing to predict adverse pathology in a man undergoing a multiparametric MRI (mpMRI) and subsequent biopsy for risk of prostate cancer. … READ MORE …

The 400,000+ CAP screening trial reports initial results

A while ago now we had first mentioned the “Cluster randomized trial of PSA testing for prostate cancer” or CAP trial — the single largest randomized trial of PSA screening for risk of prostate cancer to be implemented. … READ MORE …